AR123691A1 - Formulaciones farmacéuticas - Google Patents
Formulaciones farmacéuticasInfo
- Publication number
- AR123691A1 AR123691A1 ARP210102751A ARP210102751A AR123691A1 AR 123691 A1 AR123691 A1 AR 123691A1 AR P210102751 A ARP210102751 A AR P210102751A AR P210102751 A ARP210102751 A AR P210102751A AR 123691 A1 AR123691 A1 AR 123691A1
- Authority
- AR
- Argentina
- Prior art keywords
- geometric mean
- tablet
- cmáx
- bexagliflozin
- tmáx
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- BTCRKOKVYTVOLU-SJSRKZJXSA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(OCCOC3CC3)=CC=2)=C1 BTCRKOKVYTVOLU-SJSRKZJXSA-N 0.000 abstract 4
- 229950003611 bexagliflozin Drugs 0.000 abstract 4
- 238000013265 extended release Methods 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 230000036470 plasma concentration Effects 0.000 abstract 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 229920001993 poloxamer 188 Polymers 0.000 abstract 1
- 229940044519 poloxamer 188 Drugs 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El perfil farmacocinético del inhibidor del SGLT2 bexagliflozina puede mejorarse si este se formula como comprimido de liberación extendida. En comparación con las formas farmacéuticas estándares de liberación inmediata, estos comprimidos pueden permitir una concentración plasmática máxima, Cₘáˣ, más baja y seguir manteniendo concentraciones plasmáticas a niveles terapéuticos durante un periodo deseado. Esto puede usarse, por ejemplo, para administrar dosis más bajas y seguir proporcionando el mismo efecto farmacológico. Reivindicación 1: Un comprimido de liberación extendida caracterizado porque comprende bexagliflozina. Reivindicación 45: Un comprimido, por ejemplo, un comprimido de cualquier reivindicación precedente, caracterizado porque comprende: bexagliflozina; dibehenato de glicerilo; óxido de polietileno; lactosa; poloxámero 188; celulosa microcristalina; dióxido de silicio coloidal; y estearato de magnesio; y opcionalmente tiene un recubrimiento que comprende alcohol polivinílico. Reivindicación 53: Una forma farmacéutica oral sólida caracterizada porque contiene bexagliflozina y que proporciona una primera Cₘáˣ plasmática media geométrica, una primera AUC₀₋ₜ media geométrica y un primer Tₘáˣ mediano en sujetos en ayuno, y proporciona una segunda Cₘáˣ plasmática media geométrica, una segunda AUC₀₋ₜ media geométrica y un segundo Tₘáˣ mediano en sujetos alimentados, donde (I) la relación de la segunda dividida por la primera Cₘáˣ media geométrica está entre 0,8 y 1.8; (II) la relación de la segunda dividida por la primera AUC₀₋ₜ media geométrica está entre 0,8 y 1,8; o (III) la relación del segundo dividido por el primer Tₘáˣ mediano está entre 0,8 y 3,0. Reivindicación 56: Un método para tratar a un sujeto que sufre de diabetes o sus síntomas, caracterizado porque comprende un paso de administrar al sujeto el comprimido de una cualquiera de las reivindicaciones 1 - 46, 51 - 52, ó 55.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/119816 WO2022073151A1 (en) | 2020-10-05 | 2020-10-05 | Pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123691A1 true AR123691A1 (es) | 2023-01-04 |
Family
ID=78463953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102751A AR123691A1 (es) | 2020-10-05 | 2021-10-05 | Formulaciones farmacéuticas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20220117898A1 (es) |
| EP (1) | EP4225273A1 (es) |
| JP (1) | JP2023544412A (es) |
| KR (1) | KR20230080461A (es) |
| CN (1) | CN116600791A (es) |
| AR (1) | AR123691A1 (es) |
| AU (1) | AU2021357691A1 (es) |
| CA (1) | CA3197660A1 (es) |
| IL (1) | IL301808A (es) |
| MX (1) | MX2023003758A (es) |
| TW (1) | TW202228721A (es) |
| WO (2) | WO2022073151A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023220930A1 (en) * | 2022-05-17 | 2023-11-23 | Increvet, Inc. | Veterinary pharmaceutical formulations cross-references to related applications |
| CN115598262B (zh) * | 2022-11-24 | 2023-03-03 | 则正(济南)生物科技有限公司 | 一种双氯芬酸钠缓释片体内外相关性评价的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9149433B2 (en) | 2004-11-30 | 2015-10-06 | Basf Corporation | Method for formation of micro-prilled polymers |
| BRPI0917196B8 (pt) | 2008-08-22 | 2021-05-25 | Theracos Sub Llc | forma cristalina de um composto sendo complexo de (2s,3r,4r,5s,6r)- 2- (4- cloro- 3- (4- (2- ciclopropoxietóxi) benzil)fenil)- 6- (hidroximetil) tetraidro- 2h- piran- 3,4,5- triol, bis(l-prolina) |
| WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| CA3023278C (en) * | 2016-05-05 | 2019-04-30 | Triastek, Inc. | Controlled release dosage form |
| CN108239055B (zh) * | 2016-12-23 | 2023-07-18 | 杭州领业医药科技有限公司 | 一种thr1442 l-天冬氨酸共晶、其制备方法及药物组合物 |
| WO2018167589A1 (en) | 2017-03-16 | 2018-09-20 | Inventia Healthcare Private Limited | Pharmaceutical composition comprising dapagliflozin |
| KR102647171B1 (ko) * | 2018-02-02 | 2024-03-15 | 노보 노르디스크 에이/에스 | Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물 |
| US20190343853A1 (en) * | 2018-04-25 | 2019-11-14 | Theracos Sub, Llc | Methods of treating hypertension |
| US20200289457A1 (en) * | 2019-03-14 | 2020-09-17 | Increvet, Inc. | Compound for the management of feline diabetes |
-
2020
- 2020-10-05 WO PCT/CN2020/119816 patent/WO2022073151A1/en active Application Filing
-
2021
- 2021-10-04 JP JP2023520478A patent/JP2023544412A/ja active Pending
- 2021-10-04 IL IL301808A patent/IL301808A/en unknown
- 2021-10-04 AU AU2021357691A patent/AU2021357691A1/en active Pending
- 2021-10-04 WO PCT/US2021/053416 patent/WO2022076328A1/en active Application Filing
- 2021-10-04 MX MX2023003758A patent/MX2023003758A/es unknown
- 2021-10-04 CA CA3197660A patent/CA3197660A1/en active Pending
- 2021-10-04 EP EP21801331.6A patent/EP4225273A1/en active Pending
- 2021-10-04 CN CN202180068795.8A patent/CN116600791A/zh active Pending
- 2021-10-04 KR KR1020237015023A patent/KR20230080461A/ko active Search and Examination
- 2021-10-05 TW TW110136972A patent/TW202228721A/zh unknown
- 2021-10-05 US US17/494,455 patent/US20220117898A1/en not_active Abandoned
- 2021-10-05 AR ARP210102751A patent/AR123691A1/es unknown
-
2023
- 2023-11-03 US US18/501,714 patent/US20240139109A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022073151A1 (en) | 2022-04-14 |
| US20240139109A1 (en) | 2024-05-02 |
| CA3197660A1 (en) | 2022-04-14 |
| WO2022076328A1 (en) | 2022-04-14 |
| MX2023003758A (es) | 2023-05-10 |
| EP4225273A1 (en) | 2023-08-16 |
| KR20230080461A (ko) | 2023-06-07 |
| IL301808A (en) | 2023-05-01 |
| AU2021357691A1 (en) | 2023-06-08 |
| US20220117898A1 (en) | 2022-04-21 |
| AU2021357691A9 (en) | 2024-08-01 |
| JP2023544412A (ja) | 2023-10-23 |
| TW202228721A (zh) | 2022-08-01 |
| CN116600791A (zh) | 2023-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123691A1 (es) | Formulaciones farmacéuticas | |
| CL2015001891A1 (es) | Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas; uso para tratar el dolor; y metodo de preparacion. (divisional de la solicitud n°2754-2014). | |
| CL2017000669A1 (es) | Forma de dosificación farmacéutica (divisional de la solicitud 1029/2014) | |
| JP2020117543A (ja) | ロキソプロフェンを含有する医薬組成物５ | |
| UY30537A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| CY1108100T1 (el) | Διαδικασια για την παρασκευη εστερων κυκλοπροπυλ καρβοξυλικου οξεος και παραγωγων | |
| AR067184A1 (es) | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica | |
| Zucchi et al. | The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue | |
| AR075369A1 (es) | Comprimidos para terapia de combinacion para el tratamiento de infecciones virales. | |
| ECSP034826A (es) | Método para fabricar una composición farmacéutica de dosis baja | |
| MX2012005689A (es) | Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos. | |
| UY27296A1 (es) | Composición farmacéutica que contiene mosaprida y pancreatina | |
| BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
| Silverberg | Atopic dermatitis prevention and treatment | |
| CO2024002256A2 (es) | Formas de dosificación gastrorretentivas de 5-hidroxitriptófano | |
| HUP0400127A2 (hu) | Paracetamolt tartalmazó lenyelhető tabletta | |
| AR066666A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
| ES2526359T3 (es) | Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos | |
| CO2023000594A2 (es) | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4- oxadiazol-3-ilo | |
| JP2024504410A (ja) | 皮膚障害を治療する方法 | |
| Fodor et al. | An observational study on the pharmacokinetics of oseltamivir in lactating influenza patients | |
| AR075058A1 (es) | Composicion farmaceutica oral para uso en enfermedades respiratorias y proceso de fabricacion | |
| JP2014058461A (ja) | オランザピン含有製剤 |